



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006104**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 11:06:00

RECEIVED : 29/09/2023 11:06:38

REPORTED : 29/09/2023 14:29:31

CLINICAL INFORMATION :UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY**GLUCOSE, POST-PRANDIAL, PLASMA**

PPBS(POST PRANDIAL BLOOD SUGAR)	96	70 - 140	mg/dL
METHOD : HEXOKINASE			

Comments

NOTE:- RECHECKED FOR POST PRANDIAL PLASMA GLUCOSE VALUES. TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

****End Of Report******Please visit www.agilusdiagnostics.com for related Test Information for this accession****Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

View Details



View Report

Page 1 Of 1

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 22000000875371**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status Final**Results****Biological Reference Interval Units****HAEMATOLOGY - CBC****CBC-5, EDTA WHOLE BLOOD****BLOOD COUNTS, EDTA WHOLE BLOOD**

Test Report Status	Final	Results	Biological Reference Interval	Units
HEMOGLOBIN (HB)				
		15.4	13.0 - 17.0	g/dL
METHOD : SLS METHOD				
RED BLOOD CELL (RBC) COUNT				
		5.03	4.5 - 5.5	mil/ μ L
METHOD : HYDRODYNAMIC FOCUSING				
WHITE BLOOD CELL (WBC) COUNT				
		4.11	4.0 - 10.0	thou/ μ L
METHOD : FLUORESCENCE FLOW CYTOMETRY				
PLATELET COUNT				
		183	150 - 410	thou/ μ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION				

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)				
		45.6	40.0 - 50.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR VOLUME (MCV)				
		90.7	83.0 - 101.0	fL
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)				
		30.6	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)				
		33.8	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER				
RED CELL DISTRIBUTION WIDTH (RDW)				
		13.0	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER				
MENTZER INDEX				
		18.0		
METHOD : CALCULATED PARAMETER				
MEAN PLATELET VOLUME (MPV)				
		11.7 High	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER				

WBC DIFFERENTIAL COUNT**Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 1 Of 17



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 2200000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
NEUTROPHILS		50	40.0 - 80.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES		39	20.0 - 40.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES		6	2.0 - 10.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS		5	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
BASOPHILS		0	0 - 2	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT		2.06	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		1.60	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.25	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.21	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.3		
METHOD : CALCULATED				

MORPHOLOGY

RBC

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

METHOD : MICROSCOPIC EXAMINATION

WBC

NORMAL MORPHOLOGY

METHOD : MICROSCOPIC EXAMINATION

PLATELETS

ADEQUATE

METHOD : MICROSCOPIC EXAMINATION

**Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 22000000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 3 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY**ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD**

E.S.R	04	0 - 14	mm at 1 hr
-------	----	--------	------------

METHOD : WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)	111.2	< 116.0	mg/dL
--------------------------------	-------	---------	-------

METHOD : CALCULATED PARAMETER

Interpretation(s)**ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-**

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (> 100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 4 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -

**Patient Ref. No. 2200000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition, GLYCOSYLATED HEMOGLOBIN(HbA1c), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 5 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 2200000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP

TYPE O

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 6 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -

**Patient Ref. No. 22000000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY**LIVER FUNCTION PROFILE, SERUM**

BILIRUBIN, TOTAL	1.18 High	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.17	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT	1.01 High	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.2	6.4 - 8.2	g/dL
METHOD : BIURET			
ALBUMIN	4.2	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN	3.0	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	20	15 - 37	U/L
METHOD : UV WITH P5P			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	30	< 45.0	U/L
METHOD : UV WITH P5P			
ALKALINE PHOSPHATASE	77	30 - 120	U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)	24	15 - 85	U/L
METHOD : GAMMA GLUTAMYL CARBOXY 4-NITROANILIDE			
LACTATE DEHYDROGENASE	152	85 - 227	U/L
METHOD : LACTATE -PYRUVATE			

GLUCOSE FASTING, FLUORIDE PLASMAFBS (FASTING BLOOD SUGAR) **106 High** Normal : < 100 mg/dL

Pre-diabetes: 100-125

Diabetes: >=126

METHOD : HEXOKINASE

**Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -

Patient Ref. No. 22000000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

KIDNEY PANEL - 1**BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN	13	6 - 20	mg/dL
---------------------	----	--------	-------

METHOD : UREASE - UV

CREATININE EGFR- EPI

CREATININE	1.31 High	0.90 - 1.30	mg/dL
------------	------------------	-------------	-------

METHOD : ALKALINE PICRATE KINETIC JAFFES

AGE	49		years
-----	----	--	-------

GLOMERULAR FILTRATION RATE (MALE)	66.73	Refer Interpretation Below	mL/min/1.73m2
-----------------------------------	-------	----------------------------	---------------

METHOD : CALCULATED PARAMETER

BUN/CREAT RATIO

BUN/CREAT RATIO	9.92	5.00 - 15.00	
-----------------	------	--------------	--

METHOD : CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID	6.1	3.5 - 7.2	mg/dL
-----------	-----	-----------	-------

METHOD : URICASE UV

TOTAL PROTEIN, SERUM

TOTAL PROTEIN	7.2	6.4 - 8.2	g/dL
---------------	-----	-----------	------

METHOD : BIURET



Page 8 Of 17

Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

ALBUMIN, SERUM

ALBUMIN 4.2 3.4 - 5.0 g/dL

METHOD : BCP DYE BINDING

GLOBULIN

GLOBULIN 3.0 2.0 - 4.1 g/dL

METHOD : CALCULATED PARAMETER

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM 136 136 - 145 mmol/L

METHOD : ISE INDIRECT

POTASSIUM, SERUM 5.01 3.50 - 5.10 mmol/L

METHOD : ISE INDIRECT

CHLORIDE, SERUM 100 98 - 107 mmol/L

METHOD : ISE INDIRECT

Interpretation(s)**Interpretation(s)**

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507		ACCESSION NO : 0022WI006076	AGE/SEX : 49 Years Male
FORTIS VASHI-CHC -SPLZD		PATIENT ID : FH.12738337	DRAWN : 29/09/2023 08:31:00
FORTIS HOSPITAL # VASHI,		CLIENT PATIENT ID: UID:12738337	RECEIVED : 29/09/2023 08:31:27
MUMBAI 440001		ABHA NO :	REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :
 UID:12738337 REQNO-1588048
 CORP-OPD
 BILLNO-150123OPCR055743
 BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-- Kidney disease outcomes quality initiative (KDOQI) guidelines state that estimation of GFR is the best overall indices of the Kidney function.

- It gives a rough measure of number of functioning nephrons. Reduction in GFR implies progression of underlying disease.

- The GFR is a calculation based on serum creatinine test.

- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and in blacks than in whites.

- Creatinine is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate.

- When kidney function is compromised, excretion of creatinine decreases with a consequent increase in blood creatinine levels. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

- This equation takes into account several factors that impact creatinine production, including age, gender, and race.

- CKD EPI (Chronic kidney disease epidemiology collaboration) equation performed better than MDRD equation especially when GFR is high (>60 ml/min per 1.73m2).. This formula has less bias and greater accuracy which helps in early diagnosis and also reduces the rate of false positive diagnosis of CKD.

References:

National Kidney Foundation (NKF) and the American Society of Nephrology (ASN).

Estimated GFR Calculated Using the CKD-EPI equation-<https://testguide.labmed.uw.edu/guideline/egfr>

Chuman JK, et al. Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Med 2022, 4:100471. 35756325

Harrison's Principle of Internal Medicine, 21st ed, pg 62 and 334

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake,OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.



Dr. Akshay Dhotre, MD
 (Reg.no. MMC 2019/09/6377)
 Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -



Patient Ref. No. 2200000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 11 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -

**Patient Ref. No. 22000000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY - LIPID

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL	242 High	< 200 Desirable 200 - 239 Borderline High >= 240 High	mg/dL
--------------------	-----------------	---	-------

METHOD : ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES	122	< 150 Normal 150 - 199 Borderline High 200 - 499 High >=500 Very High	mg/dL
---------------	-----	--	-------

METHOD : ENZYMATIC ASSAY

HDL CHOLESTEROL	55	< 40 Low >=60 High	mg/dL
-----------------	----	-----------------------	-------

METHOD : DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT	159 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >= 190 Very High	mg/dL
-------------------------	-----------------	---	-------

METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL	187 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---------------------	-----------------	--	-------

METHOD : CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN	24.4	<= 30.0	mg/dL
------------------------------	------	---------	-------

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO	4.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
----------------	-----	--	--

METHOD : CALCULATED PARAMETER



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 2200000875343



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
LDL/HDL RATIO		2.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

METHOD : CALCULATED PARAMETER

Interpretation(s)**Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist

Page 13 Of 17



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 22000000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS : C000045507**FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :UID:12738337 REQNO-1588048
CORP-OPD
BILLNO-150123OPCR055743
BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS**KIDNEY PANEL - 1****PHYSICAL EXAMINATION, URINE**

COLOR	PALE YELLOW
METHOD : PHYSICAL	
APPEARANCE	CLEAR
METHOD : VISUAL	

CHEMICAL EXAMINATION, URINE

PH	7.0	4.7 - 7.5
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD		
SPECIFIC GRAVITY	1.015	1.003 - 1.035
METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)		
PROTEIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		
GLUCOSE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE		
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT		
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY		

Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist**Dr. Rekha Nair, MD**
(Reg No. MMC 2001/06/2354)
Microbiologist

Page 14 Of 17



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 2200000875343**



MC-5837

PATIENT NAME : MR.ABHINAV CHATTERJI**REF. DOCTOR :****CODE/NAME & ADDRESS :** C000045507FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD : MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-1 0-5 /HPF

METHOD : MICROSCOPIC EXAMINATION

EPITHELIAL CELLS 0-1 0-5 /HPF

METHOD : MICROSCOPIC EXAMINATION

CASTS NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

REMARKS URINARY MICROSCOPIC EXAMINATION DONE ON URINARY
CENTRIFUGED SEDIMENT**Interpretation(s)****Dr. Akshay Dhotre, MD**
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist**Dr. Rekha Nair, MD**
(Reg No. MMC 2001/06/2354)
Microbiologist

Page 15 Of 17



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**Patient Ref. No. 22000000875343**

PATIENT NAME : MR.ABHINAV CHATTERJI

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3	96.1	80.0 - 200.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
T4	5.95	5.10 - 14.10	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
TSH (ULTRASENSITIVE)	1.750	0.270 - 4.200	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE,SANDWICH IMMUNOASSAY			

Interpretation(s)



Dr. Akshay Dhotre, MD
(Reg,no. MMC 2019/09/6377)
Consultant Pathologist

Page 16 Of 17



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000875343

PATIENT NAME : MR.ABHINAV CHATTERJI

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : **0022WI006076**

PATIENT ID : FH.12738337

CLIENT PATIENT ID: UID:12738337

ABHA NO :

AGE/SEX : 49 Years Male

DRAWN : 29/09/2023 08:31:00

RECEIVED : 29/09/2023 08:31:27

REPORTED : 29/09/2023 14:00:33

CLINICAL INFORMATION :

UID:12738337 REQNO-1588048

CORP-OPD

BILLNO-150123OPCR055743

BILLNO-150123OPCR055743

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN	0.650	0.0 - 2.0	ng/mL
---------------------------	-------	-----------	-------

METHOD : ELECTROCHEMILUMINESCENCE,SANDWICH IMMUNOASSAY

Interpretation(s)

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. - PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patients.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.

- As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines.

- Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-10 ng/mL.

- Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

References-

1. Burtis CA, Ashwood ER, Bruns DE. Teitz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.
2. Williamson MA, Snyder LM, Wallach's interpretation of diagnostic tests, 9th edition.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Akshay Dhotre, MD
(Reg.no. MMC 2019/09/6377)
Consultant Pathologist



View Details



View Report

Page 17 Of 17

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 2200000875343